Navigation Links
Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
Date:3/19/2009

ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr. Bhaskar Chaudhuri to the position of President, Valeant Pharmaceuticals International, effective March 10, 2009. In this role, Dr. Chaudhuri will assume responsibility for overseeing the Dow Services business, corporate business development activities, the branded generics operations in Mexico and Poland, and will be a member of Valeant's Executive Management Team.

About Dr. Bhaskar Chaudhuri

Prior to joining Valeant upon the Company's acquisition of Dow Pharmaceutical Sciences, Inc. on December 31, 2008, Dr. Chaudhuri served for seven years as President and Chief Executive Officer and a Member of Dow's Board of Directors. Before joining Dow, Dr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories, where he oversaw the research and development activities for its Cardiovascular, Neurology and Dermatology businesses, as well as a segment of its manufacturing operations.

Prior to his positions at Bertek, Dr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri joined Mylan through the acquisition of Penederm Inc., where he was the Vice President of R&D from 1992 to 1998.

Dr. Chaudhuri has over 20 years experience in pharmaceutical management service, research and development. He holds a Doctorate in Physical Pharmacy, a Masters of Science in Industrial Pharmacy and a Bachelors of Science in Pharmacy.

As is the case with other members of Valeant's senior management, Dr. Chaudhuri's compensation package is directly linked to the performance of Valeant and is intended to provide a strong and direct link to the company's future.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the future of Valeant's business and performance. These statements are based upon the current expectations and beliefs of Valeant's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to Valeant's ability to successfully integrate its acquisitions and to realize the benefits of these acquisitions and management's ability to improve operations, as well as other risks and uncertainties discussed in the company's filings with the SEC. The company cautions the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. The company also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this press release. The company undertakes no responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... The ... and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has ... law clerk for the firm, will concentrate her practice in elder law, Medicaid planning ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... How to Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path ... to Learning How to Walk with God #TruthwithGrace” is the creation of published ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oklahoma City Convention Center at 10 North Broadway Avenue, will be an educational ... of relevant, practical instruction in the management of chronic pain. , Oklahoma is ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
(Date:3/23/2017)... LONDON , March 23, 2017 ... the years along with the prevalence of allergic ... preventative measures are currently revolutionising the ways in ... Allergies 2017 promises to be both ... discussion amongst the allergy interest groups, immunologists, research ...
(Date:3/23/2017)... March 23, 2017 ... Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline ... Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) ... condition characterized by recurrent kidney and bladder stones. ... called oxalate. Symptoms include blood in the urine, ...
Breaking Medicine Technology: